Merz Therapeutics acquires INBRIJA and FAMPYRA from Acorda Therapeutics to bolster neurological portfolio
In a strategic move enhancing its presence in the neurology sector, Merz Therapeutics has successfully completed the acquisition of INBRIJA (levodopa inhalation powder) and FAMPYRA (fampridine), along with related assets, from Acorda Therapeutics, Inc. This transaction, valued at USD 185 million in cash, was conducted through a court-structured 363 sale under the U.S. Bankruptcy Code, […]